Organized interventions to improve health based on the principles and procedures developed through the health sciences are provided by practitioners trained in medicine, nursing, nutrition, pharmacy, social work, psychology, occupational therapy, physical therapy and other health care professions. Clinical practitioners focus mainly on the health of individuals, while public health practitioners consider the overall health of communities and populations. Workplace wellness programs are increasingly adopted by companies for their value in improving the health and well-being of their employees, as are school health services in order to improve the health and well-being of children.
Laboratory evidence indicated that cannabidiol may reduce THC clearance, increasing plasma concentrations which may raise THC availability to receptors and enhance its effect in a dose-dependent manner. In vitro, cannabidiol inhibited receptors affecting the activity of voltage-dependent sodium and potassium channels, which may affect neural activity. A small clinical trial reported that CBD partially inhibited the CYP2C-catalyzed hydroxylation of THC to 11-OH-THC.
Via CB1 receptor activation, THC indirectly increases dopamine release and produces psychotropic effects. Cannabidiol (CBD) also acts as an allosteric modulator of the μ- and δ-opioid receptors. THC also potentiates the effects of the glycine receptors. It is unknown if or how these actions contribute to the effects of cannabis.
Last year, the National Academies of Sciences, Engineering and Medicine released a nearly 500-page report on the health effects of cannabis and cannabinoids. A committee of 16 experts from a variety of scientific and medical fields analyzed the available evidence — more than 10,000 scientific abstracts in all. Because so few studies examine the effects of CBD on its own, the panel did not issue any findings about CBD specifically, but it did reach some conclusions about cannabis and cannabinoids more generally. The researchers determined that there is “conclusive or substantial evidence” supporting the use of cannabis or cannabinoids for chronic pain in adults, multiple sclerosis-related spasticity (a kind of stiffness and muscle spasms), and chemotherapy-induced nausea and vomiting. The committee also found “moderate” evidence that cannabis or cannabinoids can reduce sleep disturbances in people with obstructive sleep apnea, fibromyalgia, chronic pain and multiple sclerosis, as well as “limited” evidence that these substances can improve symptoms of Tourette’s syndrome, increase appetite and stem weight loss in people with HIV/AIDs, and improve symptoms of PTSD and anxiety.
The heat is very much on CBD oil sellers these days as the FDA continues to crack down on companies selling “questionable” (to put it nicely) hemp-based products. In fact, since 2015 – when the FDA first issued warning letters to multiple CBD sellers – the industry has been forced to clean up its act, at least in terms of manufacturing operations and brand transparency.
Cannabis smoke contains thousands of organic and inorganic chemical compounds. This tar is chemically similar to that found in tobacco smoke, and over fifty known carcinogens have been identified in cannabis smoke, including; nitrosamines, reactive aldehydes, and polycylic hydrocarbons, including benz[a]pyrene. Cannabis smoke is also inhaled more deeply than is tobacco smoke. As of 2015, there is no consensus regarding whether cannabis smoking is associated with an increased risk of cancer. Light and moderate use of cannabis is not believed to increase risk of lung or upper airway cancer. Evidence for causing these cancers is mixed concerning heavy, long-term use. In general there are far lower risks of pulmonary complications for regular cannabis smokers when compared with those of tobacco. A 2015 review found an association between cannabis use and the development of testicular germ cell tumors (TGCTs), particularly non-seminoma TGCTs. A 2015 analysis of six studies found little evidence that long-term or regular cannabis smoking was associated with lung cancer risk, though it could not rule out whether an association with heavy smoking exists. Another 2015 meta-analysis found no association between lifetime cannabis use and risk of head or neck cancer. Combustion products are not present when using a vaporizer, consuming THC in pill form, or consuming cannabis foods.
Hemp stalk is baled for transportation and long-term storage using traditional farming balers. Large round balers are best for hemp because they allow for more thorough drying as they don’t pack the hemp as tightly as square balers. Hemp should be stored in a dry environment in conditions intended to reduce as much absorbable air moisture as possible. It’s also important to check for wet patches during baling to further avoid mold.
In a double-blind, placebo-controlled study, 24 smokers were randomly chosen to receive either an inhaler of CBD oil or a placebo. Participants were asked to take a puff every time they had an urge to puff a cigarette. Over the week, those with placebo inhalers saw no change in their total number of cigarettes consumed, while those who were taking CBD saw a nearly 40 percent drop in their intake. Using the inhaler decreased the number of cigarettes without increasing their craving for nicotine, pointing towards a purpose for Cannabidiol in the withdrawal process.
As the number of service sector jobs has risen in developed countries, more and more jobs have become sedentary, presenting a different array of health problems than those associated with manufacturing and the primary sector. Contemporary problems, such as the growing rate of obesity and issues relating to stress and overwork in many countries, have further complicated the interaction between work and health.
In 2019, the European Commission announced that CBD and other cannabinoids would be classified as "novel foods", meaning that CBD products would require authorization under the EU Novel Food Regulation stating: because "this product was not used as a food or food ingredient before 15 May 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required." The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019. If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021.
Earliest reference to euphoric use of C. sativa appears to date to China of 5 millennia ago, but it was in India over the last millennium that drug consumption became more firmly entrenched than anywhere else in the world. Not surprisingly, the most highly domesticated drug strains were selected in India. While C. sativa has been used as a euphoriant in India, the Near East, parts of Africa, and other Old World areas for thousands of years, such use simply did not develop in temperate countries where hemp was raised. The use of C. sativa as a recreational inebriant in sophisticated, largely urban settings is substantially a 20th century phenomenon.
Fiberboard. In North America the use of nonwood fibers in sheet fiberboard (“pressboard” or “composite board”) products is relatively undeveloped. Flax, jute, kenaf, hemp, and wheat straw can be used to make composite board. Wheat straw is the dominant nonwood fiber in such applications. Although it might seem that hemp bast fibers are desirable in composite wood products because of their length and strength, in fact the short fibers of the hurds have been found to produce a superior product (K. Domier, pers. commun.). Experimental production of hemp fiberboard has produced extremely strong material (Fig. 22). The economic viability of such remains to be tested. Molded fiberboard products are commercially viable in Europe (Fig. 23), but their potential in North America remains to be determined.
Fatty Acids. The quality of an oil or fat is most importantly determined by its fatty acid composition. Hemp is of high nutritional quality because it contains high amounts of unsaturated fatty acids, mostly oleic acid (C18:1, 10%–16%), linoleic acid (C18:2, 50%–60%), alpha-linolenic acid (C18:3, 20%–25%), and gamma-linolenic acid (C18:3, 2%–5%) (Fig. 37). Linoleic acid and alpha-linolenic acid are the only two fatty acids that must be ingested and are considered essential to human health (Callaway 1998). In contrast to shorter-chain and more saturated fatty acids, these essential fatty acids do not serve as energy sources, but as raw materials for cell structure and as precursors for biosynthesis for many of the body’s regulatory biochemicals. The essential fatty acids are available in other oils, particularly fish and flaxseed, but these tend to have unpleasant flavors compared to the mellow, slightly nutty flavor of hempseed oil. While the value of unsaturated fats is generally appreciated, it is much less well known that the North American diet is serious nutritionally unbalanced by an excess of linoleic over alpha-linonenic acid. In hempseed, linoleic and alpha-linolenic occur in a ratio of about 3:1, considered optimal in healthy human adipose tissue, and apparently unique among common plant oils (Deferne and Pate 1996). Gamma-linolenic acid or GLA is another significant component of hemp oil (1%–6%, depending on cultivar). GLA is a widely consumed supplement known to affect vital metabolic roles in humans, ranging from control of inflammation and vascular tone to initiation of contractions during childbirth. GLA has been found to alleviate psoriasis, atopic eczema, and mastalgia, and may also benefit cardiovascular, psychiatric, and immunological disorders. Ageing and pathology (diabetes, hypertension, etc.) may impair GLA metabolism, making supplementation desirable. As much as 15% of the human population may benefit from addition of GLA to their diet. At present, GLA is available in health food shops and pharmacies primarily as soft gelatin capsules of borage or evening primrose oil, but hemp is almost certainly a much more economic source. Although the content of GLA in the seeds is lower, hemp is far easier to cultivate and higher-yielding. It is important to note that hemp is the only current natural food source of GLA, i.e. not requiring the consumption of extracted dietary supplements. There are other fatty acids in small concentrations in hemp seed that have some dietary significance, including stearidonic acid (Callaway et al. 1996) and eicosenoic acid (Mölleken and Theimer 1997). Because of the extremely desirable fatty acid constitution of hemp oil, it is now being marketed as a dietary supplement in capsule form (Fig. 38).
Born in the foothills of the Rocky Mountains, we’ve been growing some of the safest and most thoroughly tested medical cannabis on the market since 2016. Our state-of-the-art facility in Cremona, Alberta, was specifically designed to keep our plants happy, and alongside a meticulous process of harvesting and curing we ensure only the best product arrives at your door.
The genus Cannabis was formerly placed in the nettle (Urticaceae) or mulberry (Moraceae) family, and later, along with the genus Humulus (hops), in a separate family, the hemp family (Cannabaceae sensu stricto). Recent phylogenetic studies based on cpDNA restriction site analysis and gene sequencing strongly suggest that the Cannabaceae sensu stricto arose from within the former family Celtidaceae, and that the two families should be merged to form a single monophyletic family, the Cannabaceae sensu lato.
These mounting developments in the elicited a problem amongst cannabis cultivators across the US: decades of selectively breeding cannabis to achieve the maximum amount of THC for a strong high reduced the overall preponderance of CBD in cultivars across the country to trace lows. Essentially, CBD had been selectively bred out of existence across the country.